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Nuclear hormone receptors function as ligand activated transcription factors. Ligand binding and modification such as acetylation have been
reported to regulate nuclear hormone receptors. The orphan receptors, Rev-erbα and Rev-erbβ, are members of the nuclear receptor superfamily
and act as transcriptional repressors. In this study, the role of recruitment of co-factors by Rev-erbβ and acetylation of Rev-erbβ in modulating
apolipoprotein CIII (apoCIII) transcription were investigated. Rev-erbβ was found to transcriptionally repress apoCIII after binding to the
apoCIII promoter. Tip60, a histone acetyl-transferase (HAT), was a novel binding partner for Rev-erbβ and recruited to the apoCIII promoter
by Rev-erbβ. Tip60 was able to acetylate Rev-erbβ and relieve the apoCIII repression mediated by Rev-erbβ. This de-repression effect
depended on acetylation of Rev-erbβ at its RXKK motif by Tip60. In addition, histone deacetylase 1 (HDAC1) interacted with Rev-erbβ and
was recruited to the apoCIII promoter by Rev-erbβ to antagonize Tip60's activity. Taken together, we have provided evidence that Rev-erbβ
modulates the apoCIII gene expression by recruiting different transcription co-activator or co-repressor.
© 2007 Elsevier B.V. All rights reserved.Keywords: Orphan nuclear receptor Rev-erbβ; Tip60; Apolipoprotein CIII; HDAC1; Acetylation1. Introduction
The family of the nuclear receptors (NRs) consists of tran-
scription factors that regulate many important biological
processes [1]. NRs have also been implicated in various
diseases such as cancer, diabetes, and osteoporosis [1]. So far,
about 50 human NRs have been identified [2]. Approximately
15% of current drugs function through interactions with NRs
[3]. The NR family is the third major target for the
pharmaceutical industry, following G protein-coupled receptors
and kinases [3]. Transcriptional activities of NRs are often
regulated by direct ligand binding and formation of a complex
with co-regulators [4,5]. However, regulation of orphan nuclear⁎ Corresponding author. Tel./fax: +86 21 65642505.
E-mail address: honglu0211@yahoo.com (H. Lu).
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doi:10.1016/j.bbamcr.2007.09.004receptors, whose ligands have not been identified, is poorly
understood.
The Rev-erb family is a sub-group of orphan receptors, two
members of which have been isolated from mammalian
genomes: Rev-erbα, also known as Ear-1 or NR1D1 and
Rev-erbβ, also known as RVR, NR1D2 or BD73 [6]. Major
differences between the two exist within the hyper-variable A/B
and D regions of the proteins. Rev-erb receptors have a broad
expression pattern and have been described as negative
transcriptional regulators [7] for many targets including N-
myc [8], Bmal1 [9], enoyl-CoA hydratase/3-hydroxyacyl-CoA
dehydrogenase bifunctional enzyme [10], α-fetoprotein [11], rat
apolipoprotein AI [12], apoCIII [13] and Rev-erbá [14].
Monomers of Rev-erbα and Rev-erbβ bind to the six-nucleotide
core motif PuGGTCA preceded by a 6-bp AT-rich region,
referred to as ROREs [15]. The activities of Rev-erb receptors
can be modified by co-factors. For example, interaction of Rev-
erbα or Rev-erbβ with a corepressor, N-CoR, enhances
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extensive research, however, it is still not clear how the
transcriptional repression mediated by Rev-erbβ or Rev-erbα is
removed.
Apolipoprotein CIII (ApoCIII) is a major component of
triglyceride-rich lipoproteins, including chylomicrons and
very low density lipoprotein (VLDL) [17]. It is well estab-
lished that the synthesis rate of apoCIII is positively correlated
with hypertriglyceridemia and over-expression of human
apoCIII gene leads to acute hypertriglyceridemia in transgenic
mice [18,19]. Hypertriglyceridemia is an independent risk
factor for coronary artery diseases [20]. In addition, triglyc-
eride-rich remnant lipoproteins are positively correlated with
progression of atherosclerosis, which remains one of the
leading causes of death in the western world [21]. Rev-erbα is
able to repress expression of apoCIII by binding to its pro-
moter directly [13]. Our recent research also provided the
evidence for the direct binding of Rev-erbβ to the promoter of
apoCIII [46].
In this report, Tip60 was recruited to the apoCIII promoter
and consequently relieved the transcriptional repression of
apoCIII by Rev-erbβ. This effect of Tip60 was achieved by
acetylation of Rev-erbβ on the RXKK motif. The process of
acetylation did not affect the binding of Rev-erbβ to the
apoCIII promoter. In addition, HDAC1 reversed the effect of
Tip60 on Rev-erbβ after recruitment to the apoCIII promoter
by Rev-erbβ. Taken together, we have confirmed that tran-
scriptional activity of Rev-erbβ can be regulated by Tip60 and
HDAC1 and established a mechanism by which transcrip-
tional repression by orphan nuclear receptors Rev-erbβ is
removed.
2. Materials and methods
2.1. Plasmids construction and protein expression
The coding sequence (CDS) of human Rev-erbβ was amplified from human
marathon liver cDNA library (Clontech) by PCR and subcloned into pET28a
(Novagen), pCMV-HA (Clontech), pCMV-Myc (Clontech), respectively. Rev-
erbβ mut1, Rev-erbβ mut2, Rev-erbβ mut3 and Rev-erbβ mut4 were generated
by PCR. The CDS of human Tip60 and HDAC1 were amplified separately from
marathon liver cDNA library (Clontech) by PCR and subcloned into pGEX4T-3
(Pharmacia Biotech), pCMV-HA (Clontech) or pCMV-Myc (Clontech) vectors.
The Tip60 HAT-defective mutant, Tip60Q377E/G380E [22], was generated by PCR
and subsequently cloned into pET28a and pCMV vector. The pET28a-Rev-erbβ
or pGEX4T-3-Tip60 was expressed in Escherichia coli strain BL21 DE3.
Purification of proteins was performed according to the manufacturer's
instruction (Novagen).
2.2. Yeast two-hybrid screening and mapping the region of Rev-erbβ
necessary for binding to Tip60
A yeast two-hybrid screen was performed using the Matchmaker GAL4
Two-hybrid system 3 (Clontech) according to the manufacturer's instruction.
Rev-erbβ was used as bait to screen the human fetal liver cDNA library
(Clontech). The mating test was used to pick out the specific interaction
between bait and prey. Based on the analysis of protein structure in SMART, the
result of yeast two-hybrid screening and also references, a series of truncated
versions of Rev-erbβ were designed. Rev-erbβΔ1 (100–579aa), Rev-erbβΔ2
(199–579aa), Rev-erbβΔ3(289–579aa), Rev-erbβΔ4(397–579aa), Rev-
erbβΔ5(1–397aa), Rev-erbβΔ6(1–289aa), Rev-erbβΔ7(1–188aa), Rev-erbβΔ8(1–101aa), and Rev-erbβΔ9(101–188aa) were generated by PCR and
subsequently cloned into pGBKT7 vector in-frame with Gal4BD. The yeast
two-hybrid system (Clontech) was used to map interacting regions of Rev-erbβ
and Tip60.
2.3. Luciferase reporter gene assay
The promoter of human apoCIII gene (nt −1408 to +24) was obtained
from human genomic DNA by PCR and subcloned into the promoter-less
luciferase reporter plasmid pGL3-basic (Promega), generating pGL3-apoCIII-
pro. Human hepatoblastoma HepG2 cells were cultured in a basal Eagle
medium supplemented with 10% (v/v) fetal calf serum. The cells seeded in
24-well plates at a density of 1×105 were co-transfected using FuGENE 6
reagent (Roche Molecular Biochemicals) with 100 ng of apoCIII's
promoter-driven luciferase expression plasmid pGL3-apoCIII-pro and
indicated amount of human Rev-erbβ-expressing plasmid pCMV-HA-Rev-
erbβ as well as 10 ng of a pRL (sea pansy) as an internal control for
transfection efficiency. The dosage of transfected plasmids in each well was
kept constant by addition of appropriate amounts of the empty vector
pCMV-HA. After 3 days, cells were lysed by 200 μl Promega lysis buffer
for 10 min at room temperature. Firefly and Renilla luciferase activities were
measured using a Dual-Luciferase® Reporter Assay Kit (Promega) on a
Lumistar luminometer (BMG Lab Technologies). Firefly luciferase activity
values were divided by Renilla luciferase activity values to obtain
normalized luciferase activities. To facilitate comparisons within a given
experiment, activity data were presented as relative luciferase activities. The
final relative activity was calculated from three independent experiments
performed in triplicate.
2.4. Chromatin immunoprecipitation
The 293T cells were co-transfected with 0.5 μg of the plasmid pGL3-
apoCIII-pro and 1 μg of either pCMV-HA-Rev-erbβ or empty vector pCMV-
HA. HepG2 cells were co-transfected with 1 μg of pCMV-HA-Rev-erbβ and
pCMV-Myc-Tip60 or pCMV-Myc-HDAC1. After incubation, a chromatin
immunoprecipitation (ChIP) assay and PCR were performed as described [23].
Purified immuno-enriched and input genomic DNA samples were also used for
real-time sequence-specific PCR reactions.
2.5. GST pull-down assay
GST-Tip60 and GST-HDAC1 fusion proteins were separately expressed in
bacteria and purified on glutathione-Sepharose (Pharmacia) as specified by the
manufacturer. The 6His-tagged Rev-erbβ protein was expressed in bacteria and
purified on Ni-nitrilotriacetic acid agarose (Qiagen). GST pull-down assays
were performed as described [24].
2.6. Co-Immunoprecipitation assay
HepG2 cells were co-transfected with pCMV-HA-Rev-erbβ and pCMV-
Myc-Tip60 or pCMV-Myc-HDAC1. At 48 h of post-transfection, cells were
collected and lysed in the TPER Lysis Buffer (Pierce). After analyzing the
expression of HA-Rev-erbβ, Myc-Tip60 or Myc-HDAC1 by western blotting
using anti-HA or anti-Myc antibody, the co-immunoprecipitation (CO-IP) assay
was carried out as described [24].
2.7. Immunofluorescence and protein subcellular localization analysis
Immunofluorescence localization was performed as described [25]. After
fixation and permeabilization, HepG2 cells were incubated with anti-Rev-erbβ
or anti-Tip60 primary antibody for 1 h at room temperature. After washing, the
cells were incubated with the secondary antibody (green and red FITC
conjugated) at a dilution of 1:50 for 1 h in a humidified chamber at room
temperature. The cells were washed by PBS and stained with 1 μg/ml of 4′, 6′-
diamidino-2-phenylindole (DAPI) to visualize nuclei and were then observed
and captured under the Olympus IX71 laser microscope.
Fig. 1. Rev-erbβ bound to the human apoCIII promoter and repressed the
activity of the promoter. (A) 293T cells were co-transfected with pCMV-HA-
Rev-erbβ and either pGL3-apoCIII-pro or pGL3-apoCIII-pro-mut. The
binding of Rev-erbβ to the apoCIII promoter was analyzed by a ChIP assay
using the anti-Rev-erbβ antibody to immunoprecipitate Rev-erbβ/DNA
complex followed by PCR. (B) HepG2 cells were co-transfected with
pGL3-apoCIII-pro or pGL3-apoCIII-pro-mut and an increasing amount of
HA-Rev-erbβ. Plasmid dosage was kept constant by addition of empty
expression vector.
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Acetylation assays in vitro were performed as described [26]. Two hundred
ng of bacterially expressed His-tagged Rev-erbβ or His-tagged Rev-erbβ
mutants were separately incubated with 5 mM [3H]acetyl-CoA and 200 ng of
either His-tagged Tip60 or His-tagged Tip60Q377E/G380E at 30 °C for 2 h. The
reaction samples were subjected to SDS-Page and acetylated Rev-erbβ was
recovered from SDS-Page. Then [3H] acetyl incorporation into the substrates
was determined by liquid scintillation counting.
2.9. Immunoprecipitation and acetyltransferase assay
HepG2 cells were co-transfected with 1 μg of pCMV-HA-Rev-erbβ and
1 μg of either pCMV-Myc-Tip60 or empty pCMV for control per 35-mm dish.
Anti-HA antibody was used to immunoprecipitate Rev-erbβ complex. After
washing 3 times with the HAT assay buffer (10% glycerol, 2 mM MgCl2,
0.5 mM EDTA, 15 μM TSA, 0.5 mM PMSF and 1 mM DTT), Rev-erbβ
complex was incubated with 5 mM [3H]acetyl-CoA in 200 μl HAT assay
buffer. HAT assays were performed as described [26]. The data were calculated
from three independent experiments performed in triplicate and presented as
means±S.D. Autoradiograph was generated by Fujifilm FLA-5100 Storage
Phosphor Imager.
2.10. Quantitative real-time PCR
Total RNA was prepared using an RNeasy kit (Qiagen). cDNA was
synthesized from RNA treated with DNase followed by reverse transcription
reaction (Invitrogen) according to manufacturer's instructions. mRNA tran-
scripts were quantified by SYBR GREEN PCR kit (Applied biosystems), using
a Prism 7900 thermal cycler and sequence detector (Applied Biosynthesis).
Forward primer (5′-GGGTACTCCTTGTTGTTGCCCT-3′) and reverse primer
(5′-CCACGGCTCTGAAGTTGGTCTGAC-3′) for apoCIII were designed to
ensure specific amplification of a 252-bp fragment of apoCIII. After
amplification, a dissociation curve was performed on all PCR products to
ensure that specific PCR products were generated. The real-time PCR results
were analyzed using the sequence detection system software V1.1 (Applied
Biosystems). The apoCIII expression levels were calculated using the
comparative CT method and normalized to expression level of β-actin that
was amplified by forward primer (5′ATGTCTCGCTCCGTGGCCTTAG 3′)
and reverse primer (5′GCTTACATGT CTCGATCCCA C 3′). All of the
transfection experiments were performed at least three times and each cDNA
sample was tested in triplicate. The data are expressed as the means±S.D.
3. Results
3.1. Rev-erbβ binds to the promoter of human apoCIII gene
and represses its activity
Rev-erbα has been reported to bind to the promoter of
human apoCIII and regulate its activity [13]. We recently also
showed that Rev-erbβ could directly bind to the promoter of
apoCIII (Wang et al., unpublished). To confirm this observa-
tion, both wild type and mutant of the apoCIII promoter were
used in this study. The promoter region of apoCIII from nt
−1408 to +24 was amplified by PCR and cloned in front of the
firefly luciferase reporter gene. pCMV-HA-Rev-erbβ and
pGL3-apoCIII-pro or pGL3-apoCIII-pro-mut were co-trans-
fected into 293T cells and incubated for 2 days followed by a
ChIP assay. As shown in Fig. 1A, Rev-erbβ was capable of
binding to the wild promoter of human apoCIII, but failed to
bind pGL3-apoCIII-pro-mut which was mutated at the half-site
of the ROREs [13]. Moreover, Rev-erbβ dramatically repressed
expression of luciferase, when pGL3-apoCIII-pro was co-transfected (Fig. 1B). The magnitude of repression was
dependent upon the amount of transfected Rev-erbβ. Con-
versely, the mutant promoter of human apoCIII was not
repressed by Rev-erbβ. These results indicate that the
interaction between Rev-erbβ and the apoCIII promoter was
specific and functional.
3.2. Rev-erbβ interacts with Tip60 in vitro and in vivo
To explore how Rev-erbβ was regulated, co-factors were
identified using a yeast two-hybrid screening and Tip60 was
found to be one of Rev-erbβ-interacting proteins. Tip60 was
originally recognized as a cellular acetyltransferase protein
that interacts with HIV-1 Tat [27]. Alternative splicing results
in the expression of at least three splice variants, Tip60
isoform 1 [28], Tip60 isoform 2 (Tip60α) [27] and Tip60
isoform 3 (Tip60β, PLA2 interacting protein, PLIP) [29].
Tip60 isoforms 1 and 3 are expressed at relatively low levels
in a broad variety of tissues and cells and exhibit cell type
specific functions [30]. The best-characterized splice variant is
isoform 2, which is also the isoform investigated in this study.
The interaction between Tip60 and Rev-erbβ was further
verified by a GST pull-down assay in vitro and a CO-IP assay
in vivo. As shown in Fig. 2A, bacterially expressed GST-
Tip60, when conjugated to glutathione-Sepharose beads,
efficiently and specifically pulled down 6His-tagged Rev-
Fig. 2. The interaction between Rev-erbβ and Tip60 was confirmed in vitro and in vivo. (A) The GST pull-down assay. GST-Tip60 was immobilized on glutathione-
Sepharose 4B beads and incubated with purified 6His-tagged Rev-erbβ from bacteria in vitro. Proteins conjugated on the beads were analyzed by western blotting
using anti-6His primary antibody. The bacterial expressed 6His-tagged Rev-erbβ was used as input (Lane 2). (B) A CO-IP assay was performed in co-transfected
HepG2 cells with 1 μg pCMV-HA-Rev-erbβ and 1 μg pCMV-Myc-Tip60. Expression of HA-Rev-erbβ and Myc-Tip60 in co-transfected cells was individually
analyzed by western blotting. Cell lysate was then precipitated by anti-Myc antibody. The precipitated proteins were eluted from the protein A/G PLUS agarose and
analyzed by western blotting using anti-HA antibody. HC represents the heavy chains of the mouse IgG. (C) HepG2 cells were transfected with 1 μg pCMV-Myc-
Tip60 or pCMV-Myc empty vector. Anti-Rev-erbβ antibody was used for precipitating proteins and anti-Myc antibody for western blotting analysis. (D) HepG2 cells
were transfected with 1 μg pCMV-HA-Rev-erbβ or pCMV-HA empty vector. Anti-Tip60 antibody was used for precipitating proteins and anti-HA antibody for
western blotting analysis. (E) An endogenous CO-IP assay was carried out by using anti-Rev-erbβ antibody to immunoprecipitate endogenous Tip60 in HepG2 cells.
Anti-Rev-erbβ antibody was used for western blotting analysis.
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performed using HepG2 cell lysates containing over-expressed
tagged proteins of HA-Rev-erbβ and Myc-Tip60. As shown in
Fig. 2B, anti-Myc antibody could immunoprecipitate HA-
tagged Rev-erbβ. Furthermore, the interaction was confirmed
by endogenous CO-IP. As shown in Fig. 2C, anti-Tip60
antibody could immunoprecipitate HA-tagged Rev-erbβ, and
anti-Rev-erbβ antibody could also immunoprecipitate Myc-
tagged Tip60 (Fig. 2D). Without transfection of any plasmid,
anti-Tip60 antibody could also immunoprecipitate endogenous
Rev-erbβ (Fig. 2E). Consistent with the yeast two hybrid
screening result, the GST pull-down and endogenous CO-IP
assays confirmed that Tip60 could bind to Rev-erbβ
specifically.
3.3. N-terminal of Rev-erbβ is required for interacting with
Tip60
To identify the region of Rev-erbβ essential for the
interaction with Tip60, serial deletion assays were performed
using the yeast two-hybrid method and the pull-down assay.
Rev-erbβ consists of five regions, A/B, C, D, and E. The highly
conserved region C is responsible for DNA binding and region
E is a putative ligand binding domain and mediates co-repressorrecruitment [16]. N- and C-terminal deletion constructs of Rev-
erbβ (Fig. 3A) were fused in-frame to GaL4 BD and tested for
their abilities to bind Tip60 by checking activation of reporter
genes Ade2, His3, and LacZ. The result showed that Tip60
bound specifically to N-terminus of Rev-erbβ (Rev-erbβΔ7)
rather than C-terminal putative ligand binding domain. To test
the strength of interactions, a semi-quantitative test of relative-
β-galactosidase activity was carried out (Fig. 3B). The Rev-
erbβ Δ51–397 had same strength of interaction as intact Rev-
erbβ did. Rev-erbβ Δ71–188 containing A/B region and DNA
binding domain (region C) revealed the strongest interaction,
suggesting that the A/B region and the DNA binding domain
(DBD) of Rev-erbβ were necessary for the interaction with
Tip60. Lengthening of Δ71–188 reduced the interaction. The
interaction between Tip60 and the serial truncated fragments of
Rev-erbβ was further verified by a GST pull-down in vitro
assay (Fig. 3C).
3.4. Subcellular co-localization of Rev-erbβ and Tip60
To determine whether the interaction between Tip60 and
Rev-erbβ might be of physiological relevance in mammalian
cells, subcellular localization and distribution of Tip60 and
Rev-erbβ in HepG2 cells were assessed using laser
Fig. 3. Regions of Rev-erbβ required for the interaction with Tip60 were
mapped. (A) Regional mapping of Rev-erbβ interacting with Tip60. All
interactions were performed by the standard yeast two-hybrid method. The
serial truncated fragments of Rev-erbβ were separately co-expressed with
full-length Tip60 in the AH109. Activation of the reporter genes suggested
that the fragments of Rev-erbβ could interact with Tip60 in yeast. The
symbol + or − indicates the presence or absence of the interaction between
Rev-erbβ and Tip60. (B) Interaction strength was evaluated by relative β-
galactosidase activity in Gal4 yeast two hybrid system. Each β-galactosidase
value was tested against the negative control of AH109 harboring Gal4AD-T
and Gal4BD-lam. Results are means±SD of three independent experiments
performed in triplicate. (C) Interactions between the serial truncated
fragments of Rev-erbβ and Tip60 were confirmed by a GST pull-down
assay.
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was identified by immunofluorescence labeling using anti-
Tip60 and anti-Rev-erbβ antibodies, respectively. As shown
in Fig. 4A and B, Rev-erbβ and Tip60 were localized in
nucleus and exhibited a punctate distribution. Co-localization
of endogenous Rev-erbβ and Tip60 in the nucleus was also
detected (Fig. 4C), implying that the interaction between these
two proteins may have physiological significance.3.5. Rev-erbβ is acetylated by Tip60
Considering that Tip60 possesses acetyl-transferase activity,
we next sought to determine whether Tip60 could acetylate
Rev-erbβ. The amino acid sequence of the Rev-erbβ was first
screened for potential acetylation sites. KxKK and RxKK have
been considered as conserved acetylation motifs for acetylation
of non-histone proteins [31,32]. Rev-erbβ does contain the
RxKK motif that exists in ER as the acetylation motif [26] and
is also homologous to the acetylation motif KxKK in p53 [23]
and AR [22]. This motif is located at residues 159–162 within
the zinc finger DNA-binding domain of Rev-erbβ. It is highly
conserved from worm to human (Fig. 5A). Next, whether
Tip60 could acetylate recombinant Rev-erbβ was assessed in
vitro by comparing the abilities of wild-type Tip60 and a HAT-
defective Tip60 mutant (Tip60Q377E/G380E) [22] to acetylate
Rev-erbβ. As shown in Fig. 5B, the purified recombinant
6His-tagged Rev-erbβ was acetylated by purified wild-type
Tip60 but not by Tip60 Q377E/G380E. Thirdly, acetylation of
Rev-erbβ by Tip60 was analyzed in HepG2 cells by
immunoprecipitation followed by an acetyltransferase assay.
HepG2 cells were transiently transfected with wild-type
pCMV-HA-Rev-erbβ and either pCMV-Myc-Tip60 or empty
vector. After 2 days of incubation, cells were lysed and anti-
HA antibody and protein A/G beads were added, followed by
1 h incubation with [3H] acetyl-CoA. The level of Rev-erbβ
acetylation was determined by measuring [3H] acetyl incor-
poration into Rev-erbβ protein using liquid scintillation
counting and autoradiography. As shown in Fig. 5C, Tip60
acetylated Rev-erbβ in HepG2 cells but did not acetylate HA
tag.
To further confirm the importance of RxKK motif and
neighboring regions in Rev-erbβ acetylation, seven lysine
residues near or in RxKK motif in wild type Rev-erbβ were
mutated to alanines to create Rev-erbβ mutants mut1–4
(Fig. 5A). The interaction intensities between Rev-erbβmutants
and Tip60 were assessed by a relative-β-galactosidase activity
assay. These point mutations did not affect the binding of Tip60
to Rev-erbβ (Fig. 5D). Equal amounts of Rev-erbβ and its
mutants were also used in the HAT assay with recombinant
GST-Tip60 (Fig. 5B). Comparing with wild Rev-erbβ protein,
acetylation ratios of Rev-erbβ mut1, mut2 and mut3 were all
reduced by about 50%, suggestive of K161/162 as the key
residues for acetylation of Rev-erbβ. The acetylation ratio of the
mut4 was about 10% lower than those in mut1–3, suggesting
that K181K184 might affect acetylation in vitro. To further
determine the effect of conserved lysines K161/162 of Rev-erbβ
on the acetylation in vivo, wild type Rev-erbβ and mut1 were
transfected into HepG2, and western blotting was performed to
detect Rev-erbβ expression. Similar amounts of wild type and
mutant Rev-erbβ were expressed by transfecting same amounts
of plasmids and confirmed by western blotting (data not
shown). The wild type and mutant Rev-erbβ were immuno-
precipitated from transfected cells by using anti-HA antibody
and incubated with [3H] acetyl-CoA. Equal amounts of wild
type and mutant Rev-erbβ were used in the HAT assay. The
acetylation ratio of the Rev-erbβ mut1 was 70% lower than the
Fig. 4. Subcellular co-localization of Rev-erbβ and Tip60 was revealed. (A) Endogenous Rev-erbβ was localized by immunofluorescence using anti-Rev-erbβ
antibody. Nuclei were stained by DAPI. (B) Endogenous Tip60 was localized by immunofluorescence using anti-Tip60 antibody. Nuclei were stained by DAPI.
(C) Endogenous Rev-erbβ and Tip60 were co-localized by immunofluorescence using anti-Rev-erbβ and anti-Tip60 antibodies.
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acetylated mutant was not detectable by autoradiography,
presumably due to its lower sensitivity comparing with liquid
scintillation counting (Fig. 5C). These results demonstrate that
the residues K161/162 of Rev-erbβwere the dominant acetylation
sites for Tip60.
3.6. Tip60 relieves Rev-erbβ mediated inhibition of apoCIII
expression by acetylating Rev-erbβ
In order to explore the potential physiological function of the
interaction between Rev-erbβ and Tip60, HepG2 cells were first
transiently co-transfected with pCMV-HA-Rev-erbβ (or
pCMV-HA-Rev-erbβ Δ1 or Δ5) and pGL3-apoCIII-pro
together with either Myc-Tip60 or empty vector. Relative
luciferase activity was used as an indicator for functionality ofthe interaction between Rev-erbβ and Tip60. As shown in Fig.
6A, Rev-erbβ inhibited expression of the reporter gene by
approximately 60%. This inhibition was removed by Tip60.
Although Rev-erbβΔ1 inhibited the expression just like Rev-
erbβ, its inhibition was not removed by Tip60, due to the fact
that Tip60 could not interact with Rev-erbβΔ1. Due to the
absence of E region (LBD), Rev-erbβΔ5 did not inhibit the
reporter gene expression. The result from co-transfection of
Tip60 and Rev-erbβΔ5 was same as the Rev-erbβΔ5 alone,
suggesting that Tip60 might be not involved in histone
modification upon the apoCIII promoter. To be more physio-
logically relevant, HepG2 cells, expressing endogenous ApoC-
III, were transiently transfected with Myc-Tip60 and/or HA-
Rev-erbβ (or HA-Rev-erbβΔ1) and the relative mRNA level of
apoCIII was measured by real-time PCR. As shown in Fig. 6B,
over-expression of Rev-erbβ repressed expression of apoCIII
Fig. 5. Tip60 acetylated RxKK motif of Rev-erbβ in vitro and in vivo. (A) Sequence comparison of DBD domain was performed with human Rev-erbβ and its
homologues in M. musculus, D. rerio, D. melanogaster and C. elegant. Residues identical in all compared sequence are presented on a black background, while
residues similar in 3 or more compared sequence are presented on a gray background. A horizontal line above sequences indicates a putative acetylation motif. Mutants
of putative acetylation sites of Rev-erbβ are also shown. (B) GST-Tip60 and GST-Tip60-mutant were immobilized separately on glutathione-Sepharose 4B beads and
incubated with 6His-tagged Rev-erbβ, Rev-erbβ mut1, Rev-erbβ mut2, Rev-erbβ mut3 or Rev-erbβ mut4 in RIPA buffer containing [3H] acetyl CoA before
measuring [3H] acetyl incorporation into the substrates by liquid scintillation counting. (C) HepG2 cells were co-transfected with 1 μg of pCMV-HA-Rev-erbβ and
1 μg of either pCMV-Myc-Tip60 or empty pCMV for control per 35-mm dish. Anti-HA antibody was used to immunoprecipitate Rev-erbβ complex. After 3 times
wash with HATassay buffer, [3H] acetyl CoAwas added into the mixture and incubated at 30 °C for 1 h. The quantity of [3H] acetyl in the substrates was measured by
liquid scintillation counting. The data were calculated from three independent experiments performed in triplicate and presented as the means±S.D. Autoradiograph
was generated by Fujifilm FLA-5100 Storage Phosphor Imager. (D) Interaction strength between Tip60 and Rev-erbβ or Rev-erbβ mutants was evaluated by relative
β-galactosidase activity. AH109 were co-transformed with plasmids pGBKT7-BD harboring different mutants of Rev-erbβ and plasmid pGBKT7-AD-Tip60. Their
relative β-galactosidase activities were measured. Results are means±SD of three independent experiments performed in triplicate.
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expressed Tip60. However, in the absence of A/B region (Rev-
erbβΔ1), Tip60 could not regulate the transcriptional activity
of Rev-erbβΔ1. These results prove that Tip60-mediated
regulation of apoCIII gene depended on the interaction with
Rev-erbβ.Tip60 was capable of acetylating Rev-erbβ, as seen in Fig. 5.
The question remained whether acetylation was involved in
Tip60-mediated relieve of Rev-erbβ inhibition of apoCIII. To
test this, both luciferase reporter system and expression of
endogenous apoCIII by real-time PCR were used for the cells
transfected with pCMV-Myc-Tip60 (or pCMV-Myc-Tip60
Fig. 6. Tip60 relieved Rev-erbβmediated inhibition of apoCIII expression by acetylating Rev-erbβ. (A) HepG2 cells were co-transfected with pGL3-apoCIII-pro and
pRL, as well as different combinations of pCMV-Myc-Tip60, pCMV-HA-Rev-erbβ, pCMV-HA-Rev-erbβΔ1 and Δ5 as indicated. Plasmid pRL was used to
normalize transfection efficiencies and the empty vector pCMV-HAwas used as a control. All luciferase activities are means±SD of three independent experiments
performed in triplicate. The bottom panel indicated similar amounts of Rev-erbβ or Rev-erbβmutants detected by western blotting with anti-HA antibody. (B) HepG2
cells were transfected with individual or combination of pCMV-myc-Tip60, pCMV-HA-Rev-erbβ and pCMV-HA-Rev-erbβΔ1. pCMV-myc empty vector was
transfected as a control. Plasmid dosage was kept constant by addition of empty expression vector. Total RNA of all samples were extracted and subjected to real-time
PCR using specific apoCIII primers. Relative endogenous apoCIII mRNA levels were calculated following normalization to β-actin. The bottom panel indicated
similar amounts of Rev-erbβ, Rev-erbβΔ1 or Rev-erbβΔ5 detected by western blotting with anti-HA antibody. (C) HepG2 cells were co-transfected with pGL3-
apoCIII-pro and pRL, as well as individual or combination of pCMV-HA-Rev-erbβ, pCMV-HA-Rev-erbβ mut1, pCMV-HA-Rev-erbβ161Q/162Q, pCMV-Myc-
Tip60 and pCMV-Myc-Tip60 mutant. The empty vector pCMV-HAwas used as a control. All luciferase activities are means±SD of three independent experiments
performed in triplicate. The bottom panel indicated similar amounts of Rev-erbβ and Rev-erbβ mut1 detected by western blotting with anti-Rev-erbβ antibody.
(D) HepG2 cells were transfectedwith individual and combination of pCMV-HA-Rev-erbβ, pCMV-HA-Rev-erbβmut1, pCMV-HA-Rev-erbβ161Q/162Q, pCMV-Myc-
Tip60 and pCMV-Myc-Tip60 mutant. Empty pCMV-HAvector was transfected as a control. Total RNAwas extracted after 36 h. Relative endogenous apoCIII mRNA
level was measured against β-actin. The bottom panel indicated similar amounts of Rev-erbβ and Rev-erbβ mut1 detected by western blotting with anti-HA antibody.
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erbβ mut1 (Fig. 6C and D). Both Rev-erbβ and Rev-erbβ mut1
inhibited activity of the apoCIII promoter, by approximately
60% based on the luciferase activities and by approximately
30% based on endogenous apoCIII expression, respectively.
Tip60 relieved Rev-erbβ-mediated repression, but not Rev-
erbβ mut1-mediated repression, due to less acetylation in themutant as seen in Fig. 5. At the same time, wild-type Tip60 and
a HAT-defective mutant Tip60 were also compared for their
abilities to remove Rev-erbβ-mediated inhibition. HepG2 cells
were transfected with HA-Rev-erbβ and either Myc-Tip60 or
HAT-defective Tip60 (Myc-Tip60Q377E/G380E mutant). Unlike
wild type Tip60, Tip60Q377E/G380E mutant without the HAT
activity could not remove Rev-erbβ-mediated inhibition
Fig. 7. Interaction between Rev-erbβ and HDAC1 was verified in vitro and in
vivo. (A) A GST pull-down assay in vitro. GST-HDAC1 or GST immobilized
on the beads was incubated with His-tagged Rev-erbβ. After thorough wash,
proteins conjugated on the beads were analyzed by western blotting using anti-
6His antibody. Lane 2 is the His-tagged Rev-erbβ input which acts as a positive
control. (B) A CO-IP assay in vivo. HepG2 cells was transfected with pCMV-
Myc-HDAC1. Expression of Myc-HDAC1 and endogenous Rev-erbβ was
analyzed by western blotting. Cell lysate was precipitated by anti-Rev-erbβ
antibody. The precipitated proteins were eluted from the protein A/G PLUS
agarose and analyzed by western blotting using anti-Myc antibody. (C) The
regions of Rev-erbβ required for interaction with HADC1 were mapped by a
pull-down assay.
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was involved in removal of the inhibition, a Rev-erbβ mutant
(K161Q/K162Q) mimicking acetylation was used in the assay.
As shown in the bar 7 of Fig. 6C and D, Rev-erbβ K161Q/
K162Q mutant lost its transcription repression to apoCIII
promoter. These results strongly support the notion that
sufficient acetylation of Rev-erbβ by Tip60 was essential to
regulate Rev-erbβ function.
3.7. Rev-erbβ interacts with HDAC1 in vitro and in vivo
The acetylation regulates the transcriptional activity of Rev-
erbβ. Next, we sought to determine the effect of deacetylation.
The histone deacetylases, HDACs, are reported to down-
regulate the transcriptional activity of numerous transcription
factors including p53 [23] and AR [22]. We thereby wondered
the possibility of a role for HDACs in Rev-erbβ functions. TSA,
a specific inhibitor of histone deacetylase, was used to test the
effect of deacetylation. When HepG2 cells were stimulated by
different concentration TSA, apoCIII mRNA level was
significantly enhanced (up to about 8-fold at 200 ng/ml of
TSA) (data not shown), indicating that the deacetylation is
probably involved in regulation of transcriptional activity of
Rev-erbβ. To identify whether HDACs involved in Rev-erbβ
regulation, HDAC1–8 were screened for interaction with Rev-
erbβ in the yeast two-hybrid system. HDAC1 were found to
interact with Rev-erbβ. The interaction between Rev-erbβ and
HDAC1 was confirmed by GST pull-down in vitro (Fig. 7A)
and in vivo CO-IP assay in HepG2 cells transfected with
pCMV-Myc-HDAC1 (Fig. 7B). To map the region of Rev-erbβ
required for the interaction with HDAC1, serial truncated
fragments of Rev-erbβ (Fig. 3A) were expressed in E. coli,
respectively, and analyzed for interaction with HDAC1 by using
the pull-down assay. As shown in Fig. 7C, the putative LBD
(Rev-erbβΔ4) was required for Rev-erbβ to bind to HDAC1.
3.8. Rev-erbβ recruits Tip60 and HDAC1 to the promoter of
apoCIII
Since Rev-erbβ interacted with both Tip60 and HDAC1
cofactors as well as the target apoCIII promoter, a logical
question was whether Tip60 and HDAC1 were associated with
the apoCIII promoter together. To answer this question, a ChIP
analysis was performed. In the absence of transfected pCMV-
HA-Rev-erbβ, relatively little apoCIII promoter DNA was
amplified when anti-Rev-erbβ antibody was used. No amplified
apoCIII promoter DNA was detectable using anti-Myc when
cells were transfected with Myc-Tip60 or Myc-HDAC1 (Fig.
8A). After transfection of pCMV-HA-Rev-erbβ, amplification
of apoCIII promoter DNA could be detected when anti-Rev-
erbβ or anti-Myc (for Myc-Tip60 and Myc-HDAC1) was used
(Fig. 8A). These results indicate that Rev-erbβ recruited Tip60
and HDAC1 to the apoCIII promoter.
Next, the possible effect of Tip60 and HDAC1 on the binding
capacity of Rev-erbβ to the apoCIII promoter was investigated.
A ChIP analysis using anti-Rev-erbβ antibody was performed
in HepG2 cells transfected with HA-Rev-erbβ alone or co-transfected with Myc-Tip60 or Myc-HDAC1. The binding
capacity of Rev-erbβ to apoCIII promoter was assessed by
quantitative PCR for ChIP DNA. As shown in Fig. 8B, Tip60
and HDAC1 did not affect Rev-erbβ binding to the apoCIII
promoter. These results prove that Rev-erbβ remained on the
apoCIII promoter after recruitment of Tip60 and HDAC1.
3.9. HDAC1 abrogates the effects of Tip60
Considering that acetylase Tip60 and deacetylase HDAC1
function oppositely upon transcriptional regulation, we won-
dered whether variation in the relative levels of these proteins
could influence the activity of Rev-erbβ. HepG2 cells were co-
transfected with increasing amounts of pCMV-Myc-HDAC1
and the same amount of pCMV-myc-Tip60 (1 μg) and pCMV-
HA-Rev-erbβ (1 μg). Co-transfection of 150 ng of pCMV-
Myc-HDAC1 only partially counteracted the effects of Tip60,
while co-transfection of 300 and 500 ng of pCMV-Myc-
HDAC1 completely abolished the effects of Tip60 (Fig. 9),
implying that dynamically recruiting different coregulators is
Fig. 8. Rev-erbβ recruited Tip60 and HDAC1 to the apoCIII promoter in
HepG2 cells and the recruitment did not affect the binding of Rev-erbβ to the
apoCIII promoter. (A) HepG2 cells (3×105) were transfected with 1 μg of
individual and combination of pCMV-HA-Rev-erbβ, pCMV-Myc-Tip60,
pCMV-Myc-HDAC1 and pCMV-Myc vector as indicated. The binding of
Tip60 or HDAC1 to the endogenous apoCIII promoter was analyzed by a ChIP
assay using the anti-Myc antibody to immunoprecipitate Tip60/Rev-erbβ/DNA
or HDAC1/Rev-erbβ/DNA complex followed by PCR. (B) Quantitative PCR
for ChIP products precipitated with anti-Rev-erbβ antibody was performed by
using promoter-specific primers. The ChIP DNA levels from co-transfected cells
with pCMV-HA-Rev-erbβ and pCMV-Myc-Tip60 or pCMV-HA-Rev-erbβ and
pCMV-Myc-HDAC1 were normalized against the PCR from ChIP product of
transfected cells with pCMV-HA-Rev-erbβ alone.
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tional activity.
4. Discussion
One important finding from this study was the revelation that
Rev-erbβ could be acetylated by Tip60. Direct co-activator
mediated acetylation of nuclear receptors has emerged as a
major determinant in regulating transcriptional activity [33],
akin to the role of phosphorylation in signal transduction
cascades. Acetylation has been reported for several nuclear
hormone receptors, including androgen receptor (AR) [22],
estrogen receptor (ER) [26] and thyroid hormone receptor (TR)
[33]. Here we report that Rev-erbβ represents an orphan nuclear
hormone receptor that can be modified by acetylation.
The regions involved in acetylation of Rev-erbβ on both
Rev-erbβ and Tip60 were also revealed. Like ER [26] and p53
[34], Rev-erbβ contains conserved acetylation motif RxKK
and was acetylated on this motif. This acetylation motif is also
homologous to the acetylation motif KxKK in p53 [23,34], AR
[22] and GATA [35]. Both Rev-erbβ and AR acetylationmotifs are located immediately carboxyl-terminal to the zinc
finger DNA-binding domain [22], while GATA-1 acetylation
motif is immediately amino-terminal to its zinc finger DNA-
binding domain [35]. Considering that the motif RxKK is next
to the DNA binding domain, modification of RxKK may
change the charges of DBD. Potentially, acetylation on the
lysines neutralizes its positive charge and increases the
hydrophobicity of Rev-erbβ, which may reduce the affinity
of DBD to DNA. However, three-dimensional modeling of
Rev-erbβ–DNA complex by dock 6.0 suggests the distance
between RxKK motif and DNA is too far to affect the affinity
of Rev-erbβ to DNA (data not shown). Consistent with the
modeling analysis result, we observed that Tip60 did not affect
Rev-erbβ binding to the apoCIII promoter (Fig. 8B).
Nevertheless, acetylation of Rev-erbβ by Tip60 regulated the
transcriptional activity of the apoCIII promoter. Similar results
have been reported by Barlev et al., who observed that
acetylation of p53 did not change the DNA binding affinity but
promoted co-activator recruitment [23]. In addition, Fu et al.
demonstrated acetylation of AR enhanced the binding of co-
activator and reduced the binding of co-repressor [31]. It is
tempting to assume that acetylation of Rev-erbβ by Tip60
removes co-repressors located on the LBD domain. However,
the possibility that acetylation of Rev-erbβ by Tip60 enhances
the binding of co-activators and reduce the binding of co-
repressors has not been fully explored in this study.
Alternatively, Tip60 could stimulate apoCIII transcription
through histone acetylation and alteration of the chromatin
structure. It is well accepted that Tip60 functions in chromatin
remodeling by acetylating histones [36,37]. However, the fact
that similar results were obtained in the luciferase reporter
system and in the cells containing endogenous apoCIII after
transfection of pCMV-myc-Tip60 and pCMV-HA-Rev-erbβ
mut1 (Fig. 6C and D) did not support the notion that Tip60
stimulates apoCIII transcription through chromatin remodeling
by acetylating histones. The balance between co-activators and
co-repressors will influence the effect of Rev-erbβ on apoCIII,
as supported by results from Rev-erbβΔ5 in comparison with
intact Rev-erbβ. Rev-erbβΔ5 has been constructed by removal
of the LBD domain from Rev-erbβ and such a change could
lead to removal of co-repressors such as HDAC1 (Fig. 7C).
HDAC1 was found to interact with Rev-erbβ directly and
reversed the effect of Tip60 on Rev-erbβ in this study.
Furthermore, histone deacetylase inhibitor TSA significantly
up-regulated expression of endogenous apoCIII (data not
shown), suggesting that deacetylation is involved in regulating
transcriptional activity of Rev-erbβ. While acetylation has been
linked to increasing transcriptional activity of targeted tran-
scription factors, deacetylation has been implicated as a
mechanism of transcription factor down-regulation [38].
HDACs play key roles in the regulation of gene activity [39]
by deacetylating nucleosome histones as well as transcription
factors, such as p53 [40] and AR [22]. The demonstration that
increasing amounts of HDAC1 counteracted the de-repression
mediated by Tip60 (Fig. 8) indicated that deacetylation by
HDAC1 was potentially involved in the transcriptional
regulation of Rev-erbβ upon apoCIII. However, the exact role
Fig. 9. HDAC1 abrogated the effect of Tip60-mediated relieving of Rev-erbβ transcription repression. (A) HepG2 cells were co-transfected with 100 ng pGL3-
apoCIII-pro, 10 ng pRL, 500 ng pCMV-HA-Rev-erbβ, 500 ng pCMV-Myc-Tip60 and various amounts of pCMV-Myc-HDAC1 (150 ng, 300 ng or 500 ng) per well.
Plasmid dosage was kept constant by addition of empty expression vector. All luciferase activities are means±SD of three independent experiments performed in
triplicate. The bottom panel indicated similar amounts of Rev-erbβ detected by western blotting with anti-Rev-erbβ antibody. (B) HepG2 cells were co-transfected
with 500 ng of pCMV-HA-Rev-erbβ, 500 ng of pCMV-Myc-Tip60 and various amounts of pCMV-Myc-HDAC1 (150 ng, 300 ng or 500 ng) per well. Plasmid dosage
was kept constant by addition of empty expression vector. Total RNA of all samples was extracted and the relative endogenous apoCIII mRNAwas determined. The
bottom panel indicated similar amounts of Rev-erbβ detected by western blotting with anti-Rev-erbβ antibody.
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be further investigated.
In addition to the new finding from this study that Tip60 and
HDAC1 were co-factors for Rev-erbβ, our previous study also
indicated that ZNHIT-1 was a co-factor for Rev-erbβ (Wang
et al., unpublished). With more research, the list for Rev-erbβ
co-factors will certainly become longer. The quest for
understanding the complex interplay among these factors
remains a challenge for future studies. It is quite possible that
a trimeric complex of Tip60, HDAC1 and Rev-erbβ exists. This
postulation is based on following observations. First, Tip60 and
HDAC1 bound to the N-terminal (Fig. 3) and C-terminal (Fig.
7C) of Rev-erbβ, respectively. Second, Rev-erbβ recruited both
Tip60 and HDAC1 to the apoCIII promoter (Fig. 8A). Third,
neither Tip60 nor HDAC1 affected Rev-erbβ binding to the
apoCIII promoter (Fig. 8B). Considering their opposite
functions, the presence of an acetylase and a deacetylase upon
the same promoter was intriguing. Nevertheless, co-binding of a
coactivator and a corepressor to other nuclear receptors has been
observed before, including AR [22], ER and RAR [41].
Antagonistically functioning proteins do exist within same
complex and this may finely tune the transcriptional response.
The binding of HADC1 and Tip60 to Rev-erbβ is expected to
be a dynamic process to keep the transcription of ApoCIII to
meet the physiological requirement. Studies on how physio-
logical and pathological conditions affect the balance between
corepressors and coactivators will certainly lead to better
understanding of physiological functions of Rev-erbβ.
Transcriptional regulation of ApoCIII by Rev-erbβ is still
elusive and might be through following postulated routes.Firstly, Rev-erbβ is an orphan nuclear receptor. However, it does
not mean that no potential ligand could bind Rev-erbβ. E75, a
drosophila orthologue of human Rev-erb, is tightly bound by
heme and NO [42], suggesting that there might be some
unidentified ligands, which could bind Rev-erbβ and regulate its
activity. Similar to ‘classical’ NRs, binding of unidentified
“ligands” to orphan nuclear receptors induce a conformational
change of the receptor and recruits or excludes co-regulators.
Secondly, some ligand-dependent nuclear hormone receptors
bind to the human apoCIII promoter and may affect Rev-erbβ
activity. In addition to two ROREs (Fig. 1A, nt −82/−18) that
mediate Rev-erbβ binding, there are other hormone response
elements (HRE) on the apoCIII promoter [43]. These HRE
could be occupied by other ligand-dependent receptor such as
the retinoid X receptor (RXR) and peroxisome proliferator-
activated receptor (PPAR)-alpha [13,43]. These ligand-depen-
dent receptors modulate the apoCIII transcription through
recruiting gigantic complexes, which might affect posttransla-
tional modifications of neighboring Rev-erbβ and thus its
interactions with coactivators and corepressors. Thirdly, there is
increasing evidence that the phosphorylation status of transcrip-
tion factors might affect not only recruitment of different
coregulators but also other posttranslational modifications, such
as acetylation [44]. For example, phosphorylation of ER
increases transcriptional activity and has been implicated in
preventing acetylation of ER [45]. There are many potential
phosphorylation sites in Rev-erbβ. However, there is no
experimental evidence so far for phosphorylation of Rev-erbβ.
In all, our data have provided a novel insight into the role of
acetylation in regulating Rev-erbβ-mediated transcription
235J. Wang et al. / Biochimica et Biophysica Acta 1783 (2008) 224–236inhibition of apoCIII and the interplay between HDAC1 and
Tip60 proteins in Rev-erbβ function. We have provided
evidence that the recruitment of different coregulators is an
important mechanism for regulating Rev-erbβ transcriptional
activity.
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